IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.
DNA immunotherapies offer a promising approach to reducing the dependency on anti-HIV drug cocktails and diminishing the emergence of drug-resistant HIV strains. They are relatively inexpensive to produce, readily scaled up, and stable at ambient temperatures.
The IGXBio lead product candidate GenePro® (∆4SHIVku2), uses a DNA construct developed through animal passaging. This approach generated a DNA construct with superior gene expression and subsequent non-infectious HIV protein production activity, which results in an enhanced immune response.
Unlike other DNA approaches, GenePro® (∆4SHIVku2) stimulates both a cellular and antibody response that can control the replication of a deadly AIDS-causing virus in primate animal models without viral protein boosts and without anti-viral therapy.